Comparative Pharmacology
Head-to-head clinical analysis: KETOPROFEN versus MECLOFENAMATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KETOPROFEN versus MECLOFENAMATE SODIUM.
KETOPROFEN vs MECLOFENAMATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
Meclofenamate sodium is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
50 mg or 100 mg orally three times daily; maximum 400 mg/day.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
Clinical Note
moderateKetoprofen + Gatifloxacin
"Ketoprofen may increase the neuroexcitatory activities of Gatifloxacin."
Clinical Note
moderateKetoprofen + Rosoxacin
"Ketoprofen may increase the neuroexcitatory activities of Rosoxacin."
Clinical Note
moderateKetoprofen + Levofloxacin
"Ketoprofen may increase the neuroexcitatory activities of Levofloxacin."
Clinical Note
moderateKetoprofen + Trovafloxacin
"Ketoprofen may increase the neuroexcitatory activities of Trovafloxacin."
2-4 hours (terminal half-life; may be prolonged in hepatic impairment or elderly)
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Renal (60-70% as metabolites and conjugates), biliary/fecal (20-30%)
Category D/X
Category C
NSAID
NSAID